Quantitative mass spectrometric immunoassay of insulin like growth factor 1.

Reported in this work are the development of mass spectrometric immunoassay (MSIA) devices and methods for the qualitative analysis of IGF-1 and -2, and the rigorous quantification of IGF-1 from human plasma. A method involving addition of SDS in moderate concentration to unfractionated plasma for disrupting IGF/IGFBP complexes was initially developed. The method is suitable for the direct extraction of the IGFs and subsequent mass spectrometric analysis. Rat plasma, containing IGF-1 that is mass shifted from human IGF-1, was used as an internal reference standard (IRS) for the quantification of IGF-1 directly from human plasma. A standard curve with linear dynamic range of at least 2 orders of magnitude was constructed from serially diluted IGF-1 standards containing equal amounts of rat plasma. Using the standard curve, IGF-1 levels in plasma samples from eight individuals were determined. The limit of detection for the IGF-1 MSIA was also evaluated and established to be approximately 15 pM. The assay is rapid and can be performed in parallel via high-throughput robotics processing. Furthermore, the mass spectrometry aspect of the developed IGF-1 immunoassay offers a new dimension in the ongoing study of IGF-1 and related diseases.

[1]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[2]  M. Bidlingmaier,et al.  Normal Values of Insulin-Like Growth Factor I and Their Clinical Utility in Adults , 2001, Hormone Research in Paediatrics.

[3]  R. Nelson,et al.  Detection of bound and free IGF‐1 and IGF‐2 in human plasma via biomolecular interaction analysis mass spectrometry , 2003, FEBS letters.

[4]  P. Cohen,et al.  IGFs and IGFBPs: role in health and disease. , 2002, Best practice & research. Clinical endocrinology & metabolism.

[5]  C. Mantzoros,et al.  Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. , 1998, Journal of the National Cancer Institute.

[6]  R. Nelson,et al.  Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins Published, JLR Papers in Press, December 1, 2002. DOI 10.1194/jlr.D200034-JLR200 , 2003, Journal of Lipid Research.

[7]  J. Tabet,et al.  Approach to the determination of insulin-like-growth-factor-I (IGF-I) concentration in plasma by high-performance liquid chromatography-ion trap mass spectrometry: use of a deconvolution algorithm for the quantification of multiprotonated molecules in electrospray ionization. , 2001, The Analyst.

[8]  V. Quarmby,et al.  Evaluation of total IGF-I assay methods using samples from Type I and Type II diabetic patients. , 2002, Journal of immunological methods.

[9]  P. Bang.  Valid measurements of total IGF concentrations in biological fluids: recommendations from the 3rd International Symposium on Insulin-like Growth Factors. , 1995, European journal of endocrinology.

[10]  R. Nelson,et al.  Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay. , 2002, Biochemical and biophysical research communications.

[11]  R. Nelson,et al.  Detection of novel truncated forms of human serum amyloid A protein in human plasma , 2003, FEBS letters.

[12]  B. Swanepoel,et al.  Growth hormone abuse in the horse: preliminary assessment of a mass spectrometric procedure for IGF-1 identification and quantitation. , 2001, Rapid communications in mass spectrometry : RCM.

[13]  B. Breier,et al.  Valid measurements of total IGF concentrations in biological fluids. Recommendations from the 3rd International Symposium on Insulin-like Growth Factors. , 1994, The Journal of endocrinology.

[14]  R. Nelson,et al.  Detection and quantification of beta-2-microglobulin using mass spectrometric immunoassay. , 2001, Analytical biochemistry.

[15]  K. Gruber,et al.  High-throughput protein characterization using mass spectrometric immunoassay. , 2002, Analytical biochemistry.

[16]  G. Brabant,et al.  Serum Insulin-Like Growth Factor I Reference Values for an Automated Chemiluminescence Immunoassay System: Results from a Multicenter Study , 2003, Hormone Research in Paediatrics.

[17]  R. Baxter.  Insulin-like growth factor binding proteins in the human circulation: a review. , 1994, Hormone research.

[18]  E. Froesch,et al.  Metabolic Effects of IGFs , 1999 .

[19]  Andrew G Renehan,et al.  Determination of IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels in serum and plasma: comparisons using the Bland-Altman method. , 2003, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[20]  M. Stampfer,et al.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. , 1998, Science.

[21]  R. Nelson,et al.  Comparative urine protein phenotyping using mass spectrometric immunoassay. , 2003, Journal of proteome research.

[22]  K. Gruber,et al.  Determination of beta-2 microglobulin levels in plasma using a high-throughput mass spectrometric immunoassay system. , 2001, Analytical chemistry.

[23]  D. Clemmons.  Commercial Assays Available for Insulin-Like Growth Factor I and Their Use in Diagnosing Growth Hormone Deficiency , 2004, Hormone Research in Paediatrics.

[24]  B. Breier,et al.  Radioimmunoassays for IGFs and IGFBPs. , 1994, Growth regulation.

[25]  R. Nelson,et al.  High-throughput analysis of human plasma proteins , 2002 .

[26]  T. Hutchens,et al.  Quantitative Determination of Proteins by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry , 1994 .

[27]  R. Nelson,et al.  Mass spectrometric immunoassay. , 1995, Analytical chemistry.